These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 23789905)

  • 1. Pegylated liposomal doxorubicin: an efficient treatment in patients with Hodgkin lymphoma relapsing after high dose therapy and stem cell transplation.
    Clozel T; Deau B; Benet C; Franchi P; Robin M; Madelaine I; Thieblemont C; de Kerviler E; Brière J; Brice P
    Br J Haematol; 2013 Sep; 162(6):846-8. PubMed ID: 23789905
    [No Abstract]   [Full Text] [Related]  

  • 2. Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: bridge to transplant.
    Casadei B; Pellegrini C; Tonialini L; Argnani L; Zinzani PL
    Hematol Oncol; 2018 Apr; 36(2):489-491. PubMed ID: 29363146
    [No Abstract]   [Full Text] [Related]  

  • 3. Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.
    Michallet AS; Guillermin Y; Deau B; Lebras L; Harel S; Amorin S; Reynes C; Salles G; Subtil F; Brice P
    Haematologica; 2015 Jul; 100(7):e269-71. PubMed ID: 25840598
    [No Abstract]   [Full Text] [Related]  

  • 4. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.
    Schmitt CJ; Dietrich S; Ho AD; Witzens-Harig M
    Ann Hematol; 2012 Mar; 91(3):391-7. PubMed ID: 21850390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
    Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
    Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
    Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
    Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
    J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot phase 2 trial of 4 months of maintenance pegylated liposomal Doxorubicin in patients with advanced ovarian cancer after complete response to platinum and Paclitaxel-based chemotherapy.
    DiSilvestro PA; Fisher M; Pearl ML; Buhl A; Chalas E; Valea FA
    Gynecol Obstet Invest; 2007; 63(1):1-6. PubMed ID: 16809933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome.
    Quereux G; Marques S; Nguyen JM; Bedane C; D'incan M; Dereure O; Puzenat E; Claudy A; Martin L; Joly P; Delaunay M; Beylot-Barry M; Vabres P; Celerier P; Sasolas B; Grange F; Khammari A; Dreno B
    Arch Dermatol; 2008 Jun; 144(6):727-33. PubMed ID: 18559761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma.
    Cooley T; Henry D; Tonda M; Sun S; O'Connell M; Rackoff W
    Oncologist; 2007 Jan; 12(1):114-23. PubMed ID: 17227906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
    Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
    Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
    Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
    Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study.
    Di Lorenzo G; Kreuter A; Di Trolio R; Guarini A; Romano C; Montesarchio V; Brockmeyer NH; De Placido S; Bower M; Dezube BJ
    J Invest Dermatol; 2008 Jun; 128(6):1578-80. PubMed ID: 18185536
    [No Abstract]   [Full Text] [Related]  

  • 14. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
    Joly F; Ray-Coquard I; Fabbro M; Donoghoe M; Boman K; Sugimoto A; Vaughan M; Reinthaller A; Vergote I; Ferrandina G; Dell'Anna T; Huober J; Pujade-Lauraine E
    Gynecol Oncol; 2011 Aug; 122(2):226-32. PubMed ID: 21575983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplant.
    Goda JS; Massey C; Kuruvilla J; Gospodarowicz MK; Wells W; Hodgson DC; Sun A; Keating A; Crump M; Tsang RW
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e329-35. PubMed ID: 22672755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hodgkin lymphoma: evolution and dilemma in radiation treatments].
    Girinsky T; Ghalibafian M; Paumier A
    Cancer Radiother; 2009 Oct; 13(6-7):479-81. PubMed ID: 19656714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience.
    Dear RF; Gao B; Harnett P
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):66-73. PubMed ID: 20398040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.
    Constantinidou A; Jones RL; Scurr M; Al-Muderis O; Judson I
    Eur J Cancer; 2009 Nov; 45(17):2930-4. PubMed ID: 19767198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated liposomal doxorubicin in the treatment of mycosis fungoides.
    Lybaek D; Iversen L
    Acta Derm Venereol; 2006; 86(6):545-7. PubMed ID: 17106606
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.